MDGL · Madrigal Pharmaceuticals, Inc.

BiotechnologyUnited StatesAnalyst view: Strong Buy

$544.51

-2.26% last session

End-of-day data · updated 2026-07-28

Mildly bullish3 bullish · 1 bearish technical signals

Consensus: Strong Buy (1.44 from 14 analysts)

To mean target: +24.8%

Market cap

$13B

Enterprise value

$12B

Trailing P/E

—

Forward P/E

44.5

Dividend yield

—

Beta

-1.06

Avg volume

Employees

2D change

—

5D change

1.45%

10D change

-0.40%

30D change

7.53%

60D change

10.86%

MTD change

7.17%

YTD change

-5.34%

Analyst Outlook

Consensus ratingStrong Buy

Recommendation mean (1–5)1.44

Covering analysts14

Mean price target$679.64

Low price target$553.00

Upside to mean target+24.8%

Analyst estimates change daily — follow the shifts on the Estimate Trends page.

Technical Analysis

RSI (14)52.2

50-day MA$517.26

200-day MA$505.60

Price vs 50-day MA+4.2%

Price vs 200-day MA+6.6%

MACD histogram-1.33

Volume vs 3-month avg0.6×

52w low $289.8852w high $602.83

Analyst sentiment over time — MDGL

Rec Mean (blue, left — higher = more bullish) vs. price targets (right).

Investment Bank Ratings as of 2026-07-27

Latest call per bank · past 12 months

Wells Fargo

Overweight

$685

+25.8% vs price

▲ raised from $0.00Initiates · 2026-07-27

Bank of America

Neutral

$542

-0.5% vs price

▼ cut from $550Maintains · 2026-06-11

Barclays

Overweight

$964

+77.0% vs price

▲ raised from $0.00Initiates · 2026-01-28

UBS

Buy

$523

-4.0% vs price

▲ raised from $458Maintains · 2025-08-12

Recent rating actions

Date	Firm	Action	Rating	Price target
2026-07-27	Wells Fargo	Initiates	Overweight	$0.00 → $685
2026-06-11	Bank of America	Maintains	Neutral	$550 → $542
2026-05-13	Truist Securities	Maintains	Buy	$640 → $709
2026-05-07	Canaccord Genuity	Maintains	Buy	$587 → $578
2026-05-07	Evercore ISI Group	Maintains	Outperform	$652 → $649
2026-05-06	HC Wainwright & Co.	Reiterates	Buy	$620
2026-02-20	Bank of America	Maintains	Neutral	$570 → $529
2026-01-28	Barclays	Initiates	Overweight	$0.00 → $964

Ratings and price targets are the published opinions of the issuing banks, compiled from Yahoo Finance rating actions — not investment advice.

Signal Summary as of 2026-07-28

RSI (14): RSI is 52 — neutral momentum, neither overbought nor oversold.
Price vs 50-day MA: Trading 4.2% above the 50-day MA ($517.26).
Price vs 200-day MA: Trading 6.6% above the 200-day MA ($505.60).
MA cross: The 50-day MA sits above the 200-day MA (golden-cross regime) — the longer-term trend points up.
MACD (12,26,9): MACD histogram is negative (-1.33) — short-term momentum is fading.
52-week range: Price sits between the 52-week low ($289.88) and high ($602.83).

MDGL Price Chart

Loading chart for MDGL…

Fundamentals

Revenue (TTM)$1.0B

EBITDA$0M

Free cash flow$0M

Operating cash flow$0M

Book value / share$23.58

Net debt / EBITDA1.5

WACC0.0%

Revenue growth127.00%

Earnings growth—

About Madrigal Pharmaceuticals, Inc.

Madrigal Pharmaceuticals, Inc., a biopharmaceutical company, focuses on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH) in the United States. It offers Rezdiffra, a liver-directed thyroid hormone receptor beta agonist for treating MASH. The company was founded in 2016 and is headquartered in West Conshohocken, Pennsylvania.

More in Biotechnology

VRTX

Vertex Pharmaceuticals Incorpor

$122B 5.7% YTD

REGN

Regeneron Pharmaceuticals, Inc.

$70B -13.3% YTD

ARGX

argenx SE

$56B 5.7% YTD

RVMD

Revolution Medicines, Inc.

$40B 136.1% YTD

ALNY

Alnylam Pharmaceuticals, Inc.

$37B -30.0% YTD

ONC

BeOne Medicines Ltd.

$34B 7.3% YTD

RPRX

Royalty Pharma plc

$34B 53.5% YTD

ROIV

Roivant Sciences Ltd.

$25B 60.0% YTD

Screen MDGL against the full market on the Radar →

Data is sourced from end-of-day snapshots and refreshed daily before the US market open — nothing on this page is real-time. Figures can contain vendor errors. This page is for information only and is not investment advice.